We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

Myeloma Patient Seminar in Italy Includes a Dash of Poetry
More than 100 people gathered in the town of Udine, Italy last week for a lively and informative myeloma patient event hosted by the Italian blood cancer patient group AIL. The organization is supported by a dedicated team of volunteers, according to IMF’s Director of Europe and the Middle East, Nadia Elkebir. Nadia delivered a well-received presentation about the IMF during the panel presentations in Udine and she reports on the many highlights of the event HERE.

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 3, 2015 is the deadline for applications. For more information and grant applications click HERE.

Bristol-Myers Squibb Announces Opening of Expanded Access Program for Elotuzumab
Bristol-Myers Squibb (BMS) has opened an expanded access protocol for its monoclonal antibody elotuzumab in combination with Revlimid® and dexamethasone. Expanded access is a process regulated by the Food and Drug Administration (FDA) that allows manufacturers to provide investigational new drugs to patients with serious diseases or conditions who cannot participate in a clinical trial. ?While data from a large, phase III randomized trial comparing elotuzumab plus Rev/dex versus Rev/dex alone is eagerly anticipated, in the interim patients may now enroll at an available site for access to this new combination therapy. The first 5 of a planned 50-60 sites are now enrolling patients with myeloma that has relapsed after 1-3 prior treatments. For eligibility criteria and site information CLICK HERE.

How to Be Safer as You Live Longer: A Patient Checklist
Effective new therapies have extended the lives of many myeloma patients. But with that wonderful benefit comes the need to stay vigilant about disease and treatment side effects, as well as health challenges facing us all as we age. In his blog this week, IMF Chairman Dr. Brian Durie offers an awareness checklist for patients. To read CLICK HERE.

Register now for the Sustainable Wellness – An Integrative Approach to Transform Your Mind, Body, and Spirit teleconference
The next Living Well With Myeloma Teleconference is Thursday, May 7, 2015. The subject is one that has been “in the news” and a hot topic in the medical world: Sustainable Wellness. Our Speaker for this topic is Dr. Matt Mumber and he has put together an excellent presentation that we feel will be beneficial to you and your group members.

Calling All Nurses: Symposium on Nursing Implications Offered in Orlando
Nurses – so essential to optimal patient outcomes – are invited to attend the IMF’s Nurse Leadership Board’s symposium, “Case Studies in Myeloma: Nursing Implications of Evolving Treatment Paradigms.” The nurse’s roles as patient manager, advocate, and educator are integrated into this engaging 1.5 CNE learning opportunity to be held April 23 in Orlando, FL. To register, CLICK HERE.

Knowledge Is Power - Especially When Choosing What to Eat
IMF Chairman Dr. Brian Durie offers his food recommendations for cancer patients in his blog this week. As many know, toxic chemicals found in processed food or on fruits and vegetables exposed to certain pesticides can be dangerous. Becoming aware and protecting yourself against these things are key, and a few new cookbooks can even help further with that. CLICK HERE to read Dr. Durie’s blog.

Can Polio or Other Viruses Treat Myeloma?
IMF Chairman Dr. Brian Durie responds in his blog this week to a recent 60 Minutes segment on using the polio virus to treat cancer. Myeloma patients may wonder if this is an option for them, but as Dr. Durie explains, the polio virus needs to be contained within the shell of a solid tumor to be effective.

FDA Grants Priority Review for Kyprolis® in Relapsed Patients
There was good news for myeloma patients this week as the FDA accepted the supplemental New Drug Application of Kyprolis (carfilzomib) for treatment by injection. The application applies to those with relapsed myeloma who have received at least one prior therapy. As part of the acceptance, the FDA granted Kyprolis priority review with a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2015.

South Dakota and West Virginia Join the Fight For Oral Parity
Governor Dennis Daugaard from South Dakota and Governor Earl Ray Tomblin from West Virginia signed SB 101 and HB 2493, respectively, earlier this week, bringing the official tally of states with oral parity laws to 37. This is a significant victory for patients and their families and will ensure that thousands will now have access to the oral anticancer medications they need. The IMF thanks Governors Daugaard and Tomblin for their leadership on this critical issue, and we will continue to provide updates on the remaining states with active oral parity campaigns: Mississippi, New Hampshire, North Carolina, North Dakota and Pennsylvania.

    next      view all